← Every company
Guardant Health Inc Patents
What Guardant Health Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
GH on carbonthat →Filings on file
57
Granted
0
Still pending
57
Filed under
1 names
57 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULESC12Q 1/6806, C12Q 1/6827, C12N 15/1065, C12Q 1/6874, C12Q 1/6886, C12Q2521/101, C12Q2521/107, C12Q2521/501, C12Q2525/161, C12Q2525/191, C12Q2535/122, C12Q2537/164, C12Q2563/131, C12Q2563/179, C12Q2565/514, C12Q2600/154Filed as GUARDANT HEALTH, INC.2026-06-26Andrew KENNEDY | pending |
| COMPUTATIONAL MODELING OF LOSS OF FUNCTION BASED ON ALLELIC FREQUENCYG16B 20/20, G16H 50/20, G16B 30/10, G16B 5/00, G16B 40/00, C12Q 1/6809, C12Q 1/6886, C12Q2600/106, C12Q2600/156Filed as GUARDANT HEALTH, INC.2026-06-22Catalin BARBACIORU | pending |
| METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULESC12Q 1/6806, C12Q 1/6827, C12N 15/1065, C12Q 1/6874, C12Q 1/6886, C12Q2521/101, C12Q2521/107, C12Q2521/501, C12Q2525/161, C12Q2525/191, C12Q2535/122, C12Q2537/164, C12Q2563/131, C12Q2563/179, C12Q2565/514, C12Q2600/154Filed as GUARDANT HEALTH, INC.2026-06-15Andrew KENNEDY | pending |
| SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATIONC12Q 1/6827, C12Q 1/6869, C12Q 1/6886, G16B 30/10, G16B 99/00, G16B 20/00, G16B 30/00, C12N 15/1065, C12Q 1/6806, C12Q 1/6874, C12Q 1/6883, C12Q2537/165, C12Q2545/114, C12Q2600/118, C12Q2600/156, C12Q2600/158, C12Q2600/16, C12Q2535/122, C12Q2563/179Filed as GUARDANT HEALTH, INC.2026-06-12AmirAli TALASAZ | pending |
| COMPOSITIONS AND METHODS FOR ISOLATING CELL-FREE DNAC12Q 1/6806, C12Q 1/6886, C12Q2600/154, C12Q2600/156, G01N2800/50, C12Q2535/122, C12Q2537/159, C12Q2563/131, C12Q2523/125, C12Q2535/131Filed as GUARDANT HEALTH, INC.2026-05-15Andrew KENNEDY | pending |
| METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSC12Q 1/6869, G16B 15/00, C12Q 1/6886, C12Q2535/122, C12Q2600/158Filed as GUARDANT HEALTH, INC.2026-05-14AmirAli TALASAZ | pending |
| TUMOR FRACTION AND OUTCOME ASSOCIATION IN A REAL-WORLD NON-SMALL CELL LUNG CANCER (NSCLC) COHORT USING A METHYLATION-BASED CIRCULATING TUMOR DNA (CTDNA) ASSAYG16B 40/00, G16B 40/20, G16H 10/60, G16H 20/00, G16B 20/20, G16B 20/00Filed as GUARDANT HEALTH, INC.2026-05-14Sean GORDON | pending |
| METHODS FOR DETECTING NUCLEIC ACID VARIANTS USING CAPTURE PROBESC12N 15/1065, C12Q 1/6806, C12Q 1/6855, C12Q 1/6886, C12Q2600/118, C12Q2600/154, C12Q2600/156, C12Q2525/191, C12Q2525/155, C12Q2535/122, C12Q2537/159Filed as GUARDANT HEALTH, INC.2026-04-22Andrew KENNEDY | pending |
| METHODS FOR DETECTING NUCLEIC ACID VARIANTSC12N 15/1065, C12Q 1/6855, C12Q 1/6806, C12Q2525/191, C12Q2525/155, C12Q2535/122, C12Q2537/159Filed as GUARDANT HEALTH, INC.2026-04-22Andrew KENNEDY | pending |
| METHODS FOR EARLY DETECTION OF CANCERC12Q 1/6886, Y02A 90/10, G16H 50/30, G16H 50/20, G16B 30/10, G16B 20/20, G01N 33/57557, C12M 1/00, C12M 1/34, C12Q 1/6806, C12Q 1/6855, C12Q 1/6869, C12Q2600/118, C12Q2600/154, C12Q2600/156, C12Q2600/158, C12Q2600/166Filed as GUARDANT HEALTH, INC.2026-04-13Stefanie Ann Ward MORTIMER | pending |
| METHODS AND APPLICATIONS OF GENE FUSION DETECTION IN CELL-FREE DNA ANALYSISG16B 30/10, G16B 30/00, G16B 40/00, G16B 40/30, G06F 18/253, G06F 18/23, C12Q 1/686, C12Q 1/6869, C12Q 1/6874, C12Q 1/6886, C12Q2537/157, C12Q2563/179Filed as GUARDANT HEALTH, INC.2026-04-13Bahram Ghaffarzadeh KERMANI | pending |
| METHODS FOR EARLY DETECTION OF CANCERC12Q 1/6886, Y02A 90/10, G16H 50/30, G16H 50/20, G16B 30/10, G16B 20/20, G01N 33/57557, C12M 1/00, C12M 1/34, C12Q 1/6806, C12Q 1/6855, C12Q 1/6869, C12Q2600/118, C12Q2600/154, C12Q2600/156, C12Q2600/158, C12Q2600/166Filed as GUARDANT HEALTH, INC.2026-04-02Stefanie Ann Ward MORTIMER | pending |
| DETECTING TUMOR-RELATED INFORMATION BASED ON METHYLATION STATUS OF CELL-FREE NUCLEIC ACID MOLECULESG16B 30/10, C12Q 1/6886, G16B 20/20, C12Q 1/6806, C12Q 1/6809, C12Q 1/6869, C12Q2600/112, C12Q2600/156Filed as GUARDANT HEALTH, INC.2026-04-02Oscar WESTESSON | pending |
| ARTIFICIAL INTELLIGENCE DRIVEN TISSUE SELECTION FOR IMPROVED MINIMAL RESIDUAL DISEASE DETECTIONC12Q 1/6886, G16H 10/40, C12Q2600/154, C12Q2600/156Filed as GUARDANT HEALTH, INC.2026-03-16Scott R. BORTNER | pending |
| DEAMINATION WORKFLOW FOR HIGH PERFORMANCE METHYLATION ANALYSISFiled as GUARDANT HEALTH, INC.2026-02-27ANDREW KENNEDY | pending |
| METHODS AND COMPOSITIONS FOR QUANTIFYING ANALYTESFiled as GUARDANT HEALTH, INC.2026-02-27MEROMIT SINGER | pending |
| COMPOSITIONS AND METHODS FOR DNA LIBRARY PREPARATION USING METHYLATION-SENSITIVE DIGESTION AND CPG-SITE DIGESTIONFiled as GUARDANT HEALTH, INC.2026-02-26ANDREW KENNEDY | pending |
| DATABASE FOR THERAPEUTIC INTERVENTIONSG16H 70/60, G16H 70/20, G16H 50/20, G16H 20/10, G16B 30/10, G16B 20/20, G16B 50/30, G16B 20/00, G16B 40/20Filed as GUARDANT HEALTH, INC.2026-02-13Helmy ELTOUKHY | pending |
| METHYLATED ENRICHMENT METHODS FOR SINGLE-MOLECULE GENETIC AND EPIGENETIC SEQUENCINGC12Q 1/6806, C12Q 1/6886, C12Q 1/6804, C12Q2600/154, C12Q2521/331, C12Q2523/125, C12Q2525/191, C12Q2535/122, C12Q2537/159, C12Q2537/164, C12Q2563/179, C12Q2565/631Filed as GUARDANT HEALTH, INC.2026-02-10Andrew KENNEDY | pending |
| TUMOR-INVOLVED MRD METHODS SELECTING FRAGMENT SIZES ENRICHED FOR CTDNAFiled as GUARDANT HEALTH, INC.2026-02-10ANDREW KENNEDY | pending |
| TISSUE-INFORMED DETECTION/MONITORING OF BIOLOGICALLY LINKED PLASMA BIOMARKERSFiled as GUARDANT HEALTH, INC.2026-02-06ANDREW KENNEDY | pending |
| DEPLETION OF NON-INFORMATIVE DNA SEQUENCES IN NGS-BASED MINIMUM RESIDUAL DISEASE DETECTION ASSAYSFiled as GUARDANT HEALTH, INC.2026-02-06ANDREW KENNEDY | pending |
| DETERMINING MUTATIONAL PROFILES IN CELL-FREE NUCLEIC ACIDSFiled as GUARDANT HEALTH, INC.2026-02-05HELMY ELTOUKHY | pending |
| QUANTIFYING CELL TYPES PRESENT IN SAMPLESFiled as GUARDANT HEALTH, INC.2026-02-05MEROMITT SINGER | pending |
| METHODS FOR DETECTING NUCLEIC ACIDS FROM CANCER CELLSFiled as GUARDANT HEALTH, INC.2026-02-02SVEN JEFFREY DUENWALD | pending |
| METHODS FOR MEASURING LINE-1 HYPOMETHYLATIONFiled as GUARDANT HEALTH, INC.2026-01-30ANNIE M. DEMAREE | pending |
| METHODS FOR DECOMPOSITION OF CELL-FREE DNA METHYLATION PATTERNS BASED ON CANCER HISTOLOGICAL SUBTYPESFiled as GUARDANT HEALTH, INC.2026-01-29ANTON VALOUEV | pending |
| COPY NUMBER ALLELIC STRAND DETERMINATIONFiled as GUARDANT HEALTH, INC.2026-01-28SEAN GORDON | pending |
| COPY NUMBER ALLELIC STRAND DETERMINATIONG16B 20/20, G16H 15/00, G16H 50/70, G16H 50/20, G16H 20/10, G16B 20/10, G16B 40/20, G16B 30/00Filed as GUARDANT HEALTH, INC.2026-01-28Sean GORDON | pending |
| PERSONALIZED MODELS TRAINED ON SYNTHETIC CANCER DATAFiled as GUARDANT HEALTH, INC.2026-01-27ALAN SELEWA | pending |
| METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTIONC12Q 1/6806, C12Q 1/6886, C12Q2600/154, C12Q2600/156, C12Q2521/301, C12Q2537/159Filed as GUARDANT HEALTH, INC.2026-01-27Andrew KENNEDY | pending |
| COMPUTER ARCHITECTURE FOR IDENTIFYING LINES OF THERAPYG16H 10/60, G16H 20/10, G16H 50/70Filed as GUARDANT HEALTH, INC.2026-01-14Naveen KUMAR | pending |
| CLASSIFICATION OF BREAST TUMORS USING DNA METHYLATION FROM LIQUID BIOPSYG16B 40/20, C12Q 1/6886, G16H 50/20, G16B 20/20, G16B 20/00, C12Q2600/112, C12Q2600/154Filed as GUARDANT HEALTH, INC.2026-01-12Catalin BARBACIORU | pending |
| CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSYG16B 40/30, C12Q 1/6886, G16H 50/20, C12Q2600/154, C12Q2600/158, G01N2800/50Filed as GUARDANT HEALTH, INC.2026-01-12Catalin BARBACIORU | pending |
| METHODS AND SYSTEMS FOR ADJUSTING TUMOR MUTATIONAL BURDEN BY TUMOR FRACTION AND COVERAGEG16B 20/50, C12Q 1/6827, C12Q 1/6886, A61P 35/00, G16B 20/20, G16B 20/40, G16B 20/10, G16B 30/00, A61K 45/00, C12Q2537/165, C12Q2600/106, C12Q2600/112, C12Q2600/118, C12Q2600/156, C12Q2600/158Filed as GUARDANT HEALTH, INC.2026-01-05Katie Julia QUINN | pending |
| METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULESC12Q 1/6806, C12Q 1/6827, C12N 15/1065, C12Q 1/6874, C12Q 1/6886, C12Q2521/101, C12Q2521/107, C12Q2521/501, C12Q2525/161, C12Q2525/191, C12Q2535/122, C12Q2537/164, C12Q2563/131, C12Q2563/179, C12Q2565/514, C12Q2600/154Filed as GUARDANT HEALTH, INC.2026-01-05Andrew KENNEDY | pending |
| METHODS FOR EARLY DETECTION OF CANCERG16H 50/20, C12Q 1/6886, G16H 20/17, G16H 50/30, G16H 50/70, G16B 20/20, G16B 25/10, G16B 40/20, C12Q2600/106, C12Q2600/154, C12Q2600/158Filed as GUARDANT HEALTH, INC.2025-12-23Ross Keating EPPLER | pending |
| METHODS FOR IDENTIFYING AND/OR DETECTING SOMATIC VARIANTSFiled as GUARDANT HEALTH, INC.2025-12-19ANDREW KENNEDY | pending |
| COMPOSITIONS AND METHODS FOR ANALYZING DNA USING A METHYLATION-DISCRIMINATING NUCLEASE AND CONVERSIONFiled as GUARDANT HEALTH, INC.2025-12-18ANDREW KENNEDY | pending |
| COMPOSITIONS AND METHODS FOR ENRICHING DNA USING SELECTION PROTECTION AND A METHYLATION-DISCRIMINATING NUCLEASEFiled as GUARDANT HEALTH, INC.2025-12-18ANDREW KENNEDY | pending |
| METHODS FOR CFDNA METHYLATION DATA MODELING USING TRANSFORMER NEURAL NETWORK ARCHITECTUREFiled as GUARDANT HEALTH, INC.2025-12-17ANTON VALOUEV | pending |
| METHODS OF NUCLEIC ACID ANALYSIS INVOLVING SIZE SEPARATIONFiled as GUARDANT HEALTH, INC.2025-11-26ANDREW KENNEDY | pending |
| NETWORK BANDWIDTH ARCHITECTURE FOR BIOINFORMATICS SYSTEMH04L 12/12, H04L 41/0896, G16H 40/20, G16H 10/60, G16H 50/70, G16H 50/20, G16B 50/30, G16B 50/20Filed as GUARDANT HEALTH, INC.2025-11-25Varsha KOHIRKAR | pending |
| TUMOR-SPECIFIC METHYLATION-BASED MULTI-OMIC METHOD FOR DETECTING GENE DELETIONS AND DRIVER MUTATIONS FROM PLASMA AND TISSUE DNAFiled as GUARDANT HEALTH, INC.2025-11-25SEAN GORDON | pending |
| PROMOTER METHYLATIONFiled as GUARDANT HEALTH, INC.2025-11-21JANICE PATTERSON | pending |
| PROBE DESIGN OF EXON CAPTURE TO IDENTIFY EXON-SKIPPING EVENTS IN RNA-SEQFiled as GUARDANT HEALTH, INC.2025-11-20SOFIA MEDINA RUIZ | pending |
| METHODS FOR DETECTING EXTRACELLULAR VESICLE-ASSOCIATED MOLECULESFiled as GUARDANT HEALTH, INC.2025-11-14ANDREW KENNEDY | pending |
| METHODS FOR ANALYZING LOW-DEPTH GENOME SEQUENCING DATA TO DETECT MINIMAL RESIDUAL DISEASEFiled as GUARDANT HEALTH, INC.2025-11-13SCOTT R. BORTNER | pending |
| METHODS FOR DETECTING SOMATIC VARIANTSFiled as GUARDANT HEALTH, INC.2025-11-06ANDREW KENNEDY | pending |
| INDIVIDUALIZED MRD ASSAY TYPE SELECTION TO MAXIMIZE PER PATIENT SENSITIVITY BASED ON COMPREHENSIVE TUMOR VARIANT PROFILINGFiled as GUARDANT HEALTH, INC.2025-11-06ANDREW KENNEDY | pending |
| USE OF CELL FREE BACTERIAL NUCLEIC ACIDS FOR DETECTION OF CANCERC12Q 1/6886, C12Q 1/689, Y02A 90/10, G16H 10/40, G16H 50/30, G16H 50/20, C12Q 1/6869, C12Q2600/156Filed as GUARDANT HEALTH, INC.2025-10-30Helmy ELTOUKHY | pending |
| METHODS FOR HIGHLY MULTI-PLEXED DETECTION AND QUANTIFICATION OF CO-LOCALIZED MEMBRANE SURFACE PROTEINSFiled as GUARDANT HEALTH, INC.2025-10-29ANDREW KENNEDY | pending |
| METHODS FOR HIGH-PLEXITY EXTRACELLULAR VESICLE PROTEIN CHARACTERIZATION THROUGH IMMUNOPCR/NGSFiled as GUARDANT HEALTH, INC.2025-10-29ANDREW KENNEDY | pending |
| METHODS FOR ANALYSIS OF DNA METHYLATIONC12Q 1/6806, C12Q 1/6869, C12Q 1/26, C12Q 1/34, C12Q 1/48, C12Q 1/6855, C12Q 1/6886, C12Q2600/112, C12Q2600/154, C12Q2600/156, C12Y 114/11, C12Y 204/01027, C12Y 305/04001, C12Q2521/539, C12Q2521/131, C12Q2537/164Filed as GUARDANT HEALTH, INC.2025-10-28Andrew KENNEDY | pending |
| QUALITY CONTROL METHOD FOR ENZYMATIC CONVERSION PROCEDURESC12Q 1/6827, C12Q 1/6886, C12N 15/1065, C12Q 1/6806, C12Q 1/6883, C12Q2600/154, C12Q2600/156, C12Q2523/125, C12Q2535/122, C12Q2521/301, C12Q2521/501, C12Q2521/539, C12Q2523/10, C12Q2525/117, C12Q2525/191Filed as GUARDANT HEALTH, INC.2025-10-28Andrew KENNEDY | pending |
| CELL-FREE DNA BLOOD-BASED TEST FOR CANCER SCREENINGG16B 20/20, C12Q 1/6886, G06N 20/00, G16B 20/00, G16B 20/10, G16B 40/20, G16B 30/00Filed as GUARDANT HEALTH, INC.2025-10-28Yupeng HE | pending |
| SCREENING APPROACHES FOR HIGH CANCER RISK INDIVIDUALSFiled as GUARDANT HEALTH, INC.2025-10-27ANDREW KENNEDY | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on GH
Company overviewEverything on GH in one place, with the price.SEC filingsWhat GH's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat GH's own officers and directors buy and sell.Planned salesSales GH insiders have filed notice of.Who owns itEvery manager reporting a position in GH.Funds holding itWhich funds and ETFs hold GH, and how big a bet.LobbyingWhat GH spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on GH's account, and who they worked for.